英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

07630 英派药业-B

午间休市 11-10 11:58:43

9.460

-0.005

-0.05%

最高9.680	最低9.215	成交量273.74万
今开9.375	昨收9.465	日振幅4.91%
总市值26.72亿	流通市值26.72亿	总股本2.82亿
成交额2,591万	换手率0.97%	流通股本2.82亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派药业-B","latestPrice":9.46,"timestamp":1794283123309,"preClose":9.465,"halted":0,"volume":2737400,"delay":0,"changeRate":-0.0005282620179608036,"floatShares":282461530,"shares":282461530,"eps":-1.294715,"marketStatus":"午间休市","change":-0.005,"latestTime":"11-10 11:58:43","open":9.375,"high":9.68,"low":9.215,"amount":25906933,"amplitude":0.049128,"askPrice":9.49,"askSize":10600,"bidPrice":9.46,"bidSize":3800,"shortable":0,"etf":0,"ttmEps":-1.052,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794286800000},"marketStatusCode":3,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":9.465,"openAndCloseTimeList":[[1794274200000,1794283200000],[1794286800000,1794297600000]],"volumeRatio":0.516654,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/07630/tweets","defaultTab":"tweets","newsList":[{"id":"1186395437","title":"英派药业-B10月股份维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1186395437","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186395437?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:41","pubTimestamp":1793868060,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司于2026年11月5日公布10月证券变动月报表。报告显示，截至2026年10月31日，公司注册股本及已发行股份总数均保持稳定，无任何新增发行、回购或注销情况。根据公告信息，截至10月底，公司股本保持不变，未来将继续依照香港联交所《上市规则》等相关法律法规的规定，履行股份及股本管理的相关信息披露义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680704705","title":"港股异动 | 英派药业-B(07630.HK)高开逾11% 拟以不超过1亿港元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2680704705","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680704705?lang=zh_cn&edition=full","pubTime":"2026-11-04 09:25","pubTimestamp":1793755542,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680670594","title":"英派药业-B(07630)拟回购不超过1亿港元公司H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680670594","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680670594?lang=zh_cn&edition=full","pubTime":"2026-11-04 06:39","pubTimestamp":1793745545,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B(07630)发布公告，董事会已议决根据于2026年6月25日举行的年度股东会上经公司股东批准并授予公司董事的一般授权，不时在香港联合交易所有限公司公开市场上购回公司H股，总金额不超过1亿港元(包括经纪佣金及印花税等交易成本)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158149718","title":"英派药业-B宣布最高1亿港元H股回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1158149718","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158149718?lang=zh_cn&edition=full","pubTime":"2026-11-04 06:26","pubTimestamp":1793744761,"startTime":"0","endTime":"0","summary":"2026年11月4日，南京英派药业股份有限公司发布自愿公告称，董事会已决议在香港联合交易所有限公司场内回购公司H股，回购总金额不超过1亿港元。本次回购基于公司于2026年6月25日年度股东会获得的一般性回购授权。公司强调，具体回购的时间、数量及价格将视市场情况而定，由董事会及其授权人士全权酌情决定，并不保证必然进行任何股份回购。公司提醒股东及潜在投资者在买卖公司证券时保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679250932","title":"英派药业-B创历史新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2679250932","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679250932?lang=zh_cn&edition=full","pubTime":"2026-10-30 11:42","pubTimestamp":1793331756,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678137090","title":"港股异动 | 英派药业-B(07630)高开逾3% IMP4297等三类管线药物最新临床数据亮相ESMO 2026大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2678137090","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678137090?lang=zh_cn&edition=full","pubTime":"2026-10-26 09:25","pubTimestamp":1792977946,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英派药业-B高开逾3%，截至发稿，涨3.55%，报10.78港元，成交额30.62万港元。消息面上，10月23日，英派药业-B发布公告，其管线药物塞纳帕利、IMP1734及IMP1707的最新临床数据已于2026年10月23日至27日在西班牙马德里举行的2026年欧洲肿瘤内科学会大会上以壁报展示。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512130.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","VXUS","KCAI","07630","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164979334","title":"英派药业-B（07630）于ESMO 2026公布塞纳帕利及两款PARP1选择性抑制剂最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1164979334","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164979334?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:46","pubTimestamp":1792745188,"startTime":"0","endTime":"0","summary":"总体人群盲态独立影像中心评估中位无进展生存期38.7个月，对照组13.6个月；风险比0.47；95%置信区间0.36–0.62；p＜0.0001。BRCA突变亚组：塞纳帕利中位PFS 49.8个月，对照组15.6个月；HR 0.41；95% CI 0.25–0.70。公司拥有包含塞纳帕利、IMP1734、IMP1707等在内的合成致死机制产品管线，并正与Eikon Therapeutics合作推进PARP1选择性抑制剂的全球临床开发。公告提示，根据香港联交所证券上市规则第18A.05条，公司无法保证塞纳帕利新增适应症开发或IMP1734、IMP1707的最终商业化成功，投资者需审慎决策。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677944812","title":"英派药业-B(07630)于2026年欧洲肿瘤内科学会大会以壁报展示塞纳帕利与选择性PARP1抑制剂IMP1734及IMP1707的最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2677944812","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677944812?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:36","pubTimestamp":1792744568,"startTime":"0","endTime":"0","summary":"英派药业-B(07630)公布，其管线药物塞纳帕利(IMP4297)、IMP1734(亦称为EIK1003)及 \nIMP1707(亦称为EIK1004)的最新临床数据已于2026年10月23日至27日在西班牙马德里举行的2026年欧洲肿瘤内科学会(ESMO)大会上以壁报展示。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggaonew/ganggugongg50.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggaonew/ganggugongg50.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677294486","title":"英派药业-B(07630.HK)于2026年欧洲肿瘤内科学会大会以壁报展示塞纳帕利与选择性PARP1抑制剂IMP1734及IMP1707的最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2677294486","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677294486?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:36","pubTimestamp":1792744568,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181360178","title":"异动解读｜英派药业-B盘中上涨9.03%，塞纳帕利获CHMP积极意见持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1181360178","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181360178?lang=zh_cn&edition=full","pubTime":"2026-10-16 11:48","pubTimestamp":1792122536,"startTime":"0","endTime":"0","summary":"10月16日，英派药业-B盘中上涨9.03%，报14.12港元，成交额3870.87万港元。消息面上，公司核心产品塞纳帕利此前获得欧洲药品管理局人用药品委员会积极意见，建议批准其用于晚期上皮性卵巢癌、输卵管癌及原发性腹膜癌的一线维持治疗，后续将提交欧盟委员会作最终决定。此外，公司9月已纳入沪深港通，叠加上半年收入1.05亿元、同比增长316.8%，核心产品商业化与国际化进展共同支撑市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"塞纳帕利获CHMP积极意见，英派药业盘中上涨","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105965472","title":"异动解读｜英派药业-B盘中下跌8.07%，塞纳帕利获批利好兑现后资金获利了结","url":"https://stock-news.laohu8.com/highlight/detail?id=1105965472","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105965472?lang=zh_cn&edition=full","pubTime":"2026-10-08 14:05","pubTimestamp":1791439539,"startTime":"0","endTime":"0","summary":"10月8日，英派药业-B盘中下跌8.07%，报13.32港元，成交额2707.82万港元。尽管公司核心产品塞纳帕利近期获得欧洲药品管理局人用药品委员会积极意见，且该药已在国内纳入医保并实现快速放量，但股价在连续上涨后出现明显获利回吐压力。此前塞纳帕利国际化里程碑落地叠加港股通纳入，推动股价阶段性走强，部分资金选择在利好兑现后锁定收益。公司是一家处于商业化阶段的生物技术企业，核心产品塞纳帕利已在中国获批用于卵巢癌一线维持治疗，并持续推进欧洲等海外市场布局。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"塞纳帕利利好兑现，英派药业盘中下跌","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172946206","title":"英派药业-B9月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1172946206","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172946206?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:39","pubTimestamp":1791189541,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司于2026年10月5日发布2026年9月股份变动月报。报告显示，截至2026年9月30日，公司法定注册股本及已发行股份数目均无变化，股本总体保持稳定。公告披露，公司的法定/注册股本为人民币282,461,530元，每股面值1元，截至9月末法定/注册股份总数为282,461,530股。本月内，此类普通H股无新增发行、无减发、无库藏股变动及注销情况。本次公告由执行董事兼首席执行官蔡遂雄签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174475215","title":"异动解读｜英派药业-B盘中上涨8.26%，塞纳帕利欧洲CHMP获批利好持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1174475215","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174475215?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:31","pubTimestamp":1790659912,"startTime":"0","endTime":"0","summary":"9月29日，英派药业-B盘中上涨8.26%，报14.03港元，成交额5400.01万港元，此前该股曾一度回调逾10%后企稳反弹。消息面上，公司核心产品塞纳帕利近期获欧洲药品管理局人用药品委员会积极意见，建议批准其用于晚期上皮性卵巢癌等维持治疗的上市许可，后续将提交欧盟委员会作出最终决定，一旦获批将可在所有欧盟成员国及欧洲经济区国家上市销售。此外，公司此前已与Pharmanovia达成独家授权协议，覆盖欧洲、中东、北非等地区，最高交易对价达4.235亿欧元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"塞纳帕利欧洲获批在望，英派药业上涨","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122893246","title":"异动解读｜英派药业-B盘中下跌8.05%，前期大涨后回调叠加生物科技板块整体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1122893246","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122893246?lang=zh_cn&edition=full","pubTime":"2026-09-24 10:12","pubTimestamp":1790215920,"startTime":"0","endTime":"0","summary":"9月24日，英派药业-B盘中下跌8.05%，报13.93港元，成交额3770.61万港元。该股此前因核心产品塞纳帕利获欧洲药品管理局（EMA）人用药品委员会（CHMP）积极意见，建议批准其用于晚期卵巢癌等维持治疗的上市许可，股价在9月21日单日大涨逾27%，盘中一度涨超40%至20.56港元，短期累计涨幅显著。经历快速拉升后，获利回吐压力加大。与此同时，生物科技板块整体承压，康方生物跌3.54%、荣昌生物跌5.71%、三生制药跌3.7%、信达生物跌3.53%，板块联动下行对个股形成拖累。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"英派药业涨后回调，生物科技板块走弱拖累","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669349171","title":"英派药业-B（07630）盘中拉升逾40% 药品Sepalna上市许可获欧洲CHMP建议批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2669349171","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669349171?lang=zh_cn&edition=full","pubTime":"2026-09-21 11:33","pubTimestamp":1789961630,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英派药业-B 盘中逆市拉升40.06%，暂报18.25港元，成交额3.25亿港元。消息面上，该公司发布公告，欧洲药品管理局人用药品委员会已通过了一项积极意见，建议批准药品Sepalna的上市许可，该药旨在用于晚期上皮性卵巢癌、输卵管癌及原发性腹膜癌的维持治疗。于CHMP建议批准后，塞纳帕利将提交至欧盟委员会作出最终决定。一旦获得欧盟委员会批准，塞纳帕利将获准在所有欧盟成员国及欧洲经济区国家上市销售。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992064","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","IPOS","BK4087","BK1161","CHMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669131578","title":"港股异动 | 英派药业-B(07630.HK)涨幅扩大逾41% 塞纳帕利国际化里程碑落地 公司入通有望持续吸引南下资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2669131578","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669131578?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:46","pubTimestamp":1789958791,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669136901","title":"英派药业-B盘初大涨逾22%，塞纳帕利获CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136901","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669136901?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:42","pubTimestamp":1789954959,"startTime":"0","endTime":"0","summary":"，英派药业-B发布公告，欧洲药品管理局（EMA）人用药品委员会（CHMP）已通过了一项积极意见，建议批准药品Sepalna®（塞纳帕利）的上市许可（MA），该药旨在用于晚期上皮性卵巢癌、输卵管癌及原发性腹膜癌的维持治疗。于CHMP建议批准后，塞纳帕利将提交至欧盟委员会（EC）作出最终决定。一旦获得欧盟委员会批准，塞纳帕利将获准在所有欧盟成员国及欧洲经济区国家上市销售。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-21/doc-inispynh5991178.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK4087","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669113660","title":"港股异动 | 英派药业-B(07630.HK)高开逾7% 塞纳帕利获CHMP积极意见 近期与Pharmanovia达成独家合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2669113660","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669113660?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:29","pubTimestamp":1789954177,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668292861","title":"重磅利好落地！塞纳帕利获欧洲药品管理局批准 英派药业-B (07630)收盘大涨15.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668292861","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668292861?lang=zh_cn&edition=full","pubTime":"2026-09-18 19:24","pubTimestamp":1789730648,"startTime":"0","endTime":"0","summary":"智通财经获悉，9月18日，创新药企英派药业-B走出明显拉升行情，全天收报13.03 港元，较前一交易日上涨 1.75 港元，涨幅15.51%。于CHMP建议批准后，塞纳帕利将提交至欧盟委员会作出最终决定。一旦获得欧盟委员会批准，塞纳帕利将获准在所有欧盟成员国及欧洲经济区国家上市销售。市场分析认为，创新药板块情绪修复叠加塞纳帕利欧洲药品管理局获批这一国际化里程碑落地，叠加港股通纳入、国内产品放量等多重利好，带动资金积极布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"重磅利好落地！塞纳帕利获欧洲药品管理局批准 英派药业-B (07630)收盘大涨15.51%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668405459","title":"英派药业-B(07630.HK)：塞纳帕利获CHMP积极意见 有望用于晚期上皮性卵巢癌、输卵管癌及原发性腹膜癌的一线维持治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2668405459","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668405459?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:51","pubTimestamp":1789728715,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.impacttherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1487},{"period":"1month","weight":-0.2535},{"period":"3month","weight":-0.2786},{"period":"6month","weight":-0.7739},{"period":"ytd","weight":-0.5291}],"compareEarnings":[{"period":"1week","weight":0.0451},{"period":"1month","weight":0.0098},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0735},{"period":"1year","weight":-0.0683},{"period":"ytd","weight":-0.0461}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京英派药业股份有限公司是一家主要从事生物技术研发和商业化的中国公司。该公司处于商业化阶段。该公司致力于在全球范围内推进基于合成致死（SL）机制的精准抗癌疗法。该公司自主研发的核心产品塞纳帕利已在中国获批上市，作为卵巢癌（OC）一线维持疗法。该公司正在研发的产品管线包PARP1/2、PARP1、ATR、WEE1、PKMYT1/WEE1、DHX9、ATM、USP1及CHK1/2等。","exchange":"SEHK","name":"英派药业-B","nameEN":"IMPACT THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英派药业-B,07630,英派药业-B股票,英派药业-B股票老虎,英派药业-B股票老虎国际,英派药业-B行情,英派药业-B股票行情,英派药业-B股价,英派药业-B股市,英派药业-B股票价格,英派药业-B股票交易,英派药业-B股票购买,英派药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}